Phase 3 N=569 A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Primary: Progression-free Survival (PFS) — 18.43; NA months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=68 A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant Recipients
Lung Transplantation
Primary: Maximum Concentration (Cmax) of Mycophenolic Acid (MPA), Mycophenolic Acid Glucuronide (MPAG) and Acyl Glucuronide Metabolite of Mycophenolic Acid (AcMPAG) at Day 4…
Phase 3 N=660 Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib.
Tetanus · Diphtheria · Acellular Pertussis
Primary: Number of Seroprotected Subjects Against Diphteria Toxoid (D) and Tetanus Toxoid (T) — 162; 164; 163; 164 Subjects
Phase 3 N=182 Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis
Pediatric Plaque Psoriasis
Primary: Number of Participants With Adverse Events — 161; 149; 140; 14 participants
Phase 3 N=498 Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Primary: Progression-free Survival (PFS) — 7.16; NA months
Phase 3 N=1,170 Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM
Type 2 Diabetes
Primary: Change in HbA1c From Baseline to Week 30 — -1.63; -1.34; -0.85 percentage of hemoglobin — p=<0.0001
Phase 3 N=252 Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment
Diabetes Mellitus, Type 2
Primary: Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF] — -0.32; -0.41; -0.44 % of hemoglobin — p=0.561
Phase 3 N=736 Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes
Type 2 Diabetes
Primary: Change in Glycated Hemoglobin (HbA1c) From Baseline to Week 30 — -1.13; -0.62 percentage of HbA1c — p=<0.0001
Phase 3 N=169 Telemedicine Interventions for Obstructive Sleep Apnea (OSA)
Sleep Apnea
Primary: Change Over 6 Months in Epworth Sleepiness Scale Score — -0.23; -1.05; 0.43; -2.62 units on a scale
Phase 3 N=287 Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma
Childhood Favorable Prognosis Hodgkin Lymphoma · Childhood Lymphocyte Depletion Hodgkin Lymphoma · Childhood Mixed Cellularity Hodgkin Lymphoma
Primary: Event Free Survival Without Receiving Radiation Therapy (EFSnoRT). — 0.49 Probability of survival
Phase 3 N=256 Velcade (Bortezomib) Consolidation After Transplant
Multiple Myeloma
Primary: Consolidation Phase: Percentage of Participants With Complete Response (CR) and Very Good Partial Response (VGPR) at Month 12 — 81.3; 92.9 percentage of participants
Phase 3 N=146 Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission
B-cell Childhood Acute Lymphoblastic Leukemia · Childhood Acute Lymphoblastic Leukemia in Remission · Graft Versus Host Disease
Primary: Estimated Percentage of Participants With Event Free Survival — 45; 54 percentage of participants
Phase 3 N=1,532 Radiation Therapy in Treating Patients With Stage II Prostate Cancer
Prostate Cancer
Primary: Overall Survival — 88.5; 88.1 percentage of participants — p=0.98
Phase 3 N=269 A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
Major Depressive Disorder
Primary: Percentage of Participants Experiencing a Treatment Emergent Adverse Event — 70.1; 75.3; 73.9; 73.1 Percentage of Participants
Phase 3 N=431 A Study to Evaluate the Efficacy of FK949E in Bipolar Disorder Patients With Major Depressive Episodes
Bipolar Disorder
Primary: Change From Baseline to End of Treatment Period I in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -10.1; -14.4; -12.6 units on a scale — p=0.034